Article
Cardiac & Cardiovascular Systems
Masaharu Masuda, Kimiko Sekiya, Mitsutoshi Asai, Osamu Iida, Shin Okamoto, Takayuki Ishihara, Kiyonori Nanto, Takashi Kanda, Takuya Tsujimura, Yasuhiro Matsuda, Yosuke Hata, Hiroyuki Uematsu, Taku Toyoshima, Naoko Higashino, Toshiaki Mano
Summary: The study compared the impact of catheter ablation on cardiac structural reverse remodelling and atrial and ventricular functional mitral regurgitation, finding similar improvements in MR after ablation in AFMR and VFMR patients. However, AFMR patients showed a greater decrease in left atrial volume after ablation, while VFMR patients showed a greater increase in LV ejection fraction. Long-term prognosis indicated a lower composite endpoint in the AFMR group compared to the VFMR group, with MR improvement patients demonstrating a lower composite endpoint compared to those without improvement.
Article
Cardiac & Cardiovascular Systems
Marco Bergonti, Ciro Ascione, Lorenzo Marcon, Thomas Pambrun, Domenico G. Della Rocca, Teba Gonzalez Ferrero, Luigi Pannone, Michael Kuhne, Paolo Compagnucci, Alice Bonomi, Andreas B. Gevaert, Matteo Anselmino, Michela Casella, Philipp Krisai, Claudio Tondo, Moises Rodriguez-Manero, Nicolas Derval, Gian-Battista Chierchia, Carlo de Asmundis, Hein Heidbuchel, Pierre Jais, Andrea Sarkozy
Summary: In this study, the Antwerp score was externally validated in a large European multi-centre cohort for predicting left ventricular ejection fraction (LVEF) recovery after atrial fibrillation (AF) ablation in patients with heart failure (HF). The score showed good discrimination and calibration, and patients with a score <2 had a higher probability of LVEF recovery. Responders also had a higher likelihood of positive ventricular remodelling, fewer HF hospitalizations, and lower mortality.
EUROPEAN HEART JOURNAL
(2023)
Article
Cardiac & Cardiovascular Systems
Jonathan M. Kalman, Ahmed M. Al-Kaisey, Ramanathan Parameswaran, Joshua Hawson, Robert D. Anderson, Michael Lim, David Chieng, Stephen A. Joseph, Alex McLellan, Joseph B. Morton, Paul B. Sparks, Geoffrey Lee, Prashanthan Sanders, Peter M. Kistler
Summary: This study aimed to determine if the timing of catheter ablation for atrial fibrillation (AF) affects arrhythmia outcomes. The results showed that there was no significant difference in the atrial arrhythmia free survival at 12 months post-ablation between patients who underwent early ablation and those who underwent delayed ablation. Other secondary outcomes also showed no significant difference. Therefore, delaying AF ablation by 12 months for antiarrhythmic drug management does not reduce the efficacy of ablation.
EUROPEAN HEART JOURNAL
(2023)
Review
Cardiac & Cardiovascular Systems
Gianluigi Bisleri, Arjun K. Pandey, Subodh Verma, Syed M. Ali Hassan, Bobby Yanagawa, Masud Khandaker, Mario Gaudino, Andrea M. Russo, Atul Verma, Deepak L. Bhatt, Andrew C. T. Ha
Summary: Hybrid ablation is a novel therapy that combines minimally invasive surgical and percutaneous catheter-based techniques for the management of atrial fibrillation (AF). Observational studies have shown approximately 70% success rates but higher risks compared to catheter-based ablation. Hybrid ablation is typically offered to patients with persistent or longstanding persistent AF, requiring two procedures. While a randomized trial demonstrated its superiority over catheter-based ablation, it also showed higher complication rates. Contemporary studies have shown a decrease in the incidence of serious complications. Additional randomized trials are needed to determine the risks, benefits, and cost effectiveness of hybrid ablation in clinical practice.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Medicine, General & Internal
Yu Jin Chung, Jin-Oh Choi, Kyoung-Min Park
Summary: Mechanical circulatory support with devices like LVAD has become common in treating end-stage heart failure. Managing arrhythmias post-implantation is crucial for long-term outcomes, with catheter ablation showing positive results in improving clinical symptoms and heart function in LVAD patients with atrial fibrillation.
Article
Cardiac & Cardiovascular Systems
Geoffroy Ditac, Pierre Jean Cottinet, Minh Quyen Le, Daniel Grinberg, Josselin Duchateau, Kevin Gardey, Arnaud Dulac, Antoine Deliniere, Christelle Haddad, Julie Boussuge-Roze, Frederic Sacher, Pierre Jais, Philippe Chevalier, Francis Bessiere
Summary: Atrial fibrillation (AF) catheter ablation procedure contributes significantly to GHG emissions, with a carbon footprint of 76.9 kg CO2-e. With approximately 600,000 annual procedures worldwide, AF catheter ablation leads to 125 tons of CO2 emissions every day, equivalent to a daily car ride of 700,000 km. Electrophysiology catheters and patches are identified as the main contributors to the carbon footprint, highlighting the importance of reducing, reusing, and recycling these items.
Article
Cardiac & Cardiovascular Systems
Karim Benali, Paul Khairy, Nefissa Hammache, Adrian Petzl, Antoine Da Costa, Atul Verma, Jason G. Andrade, Laurent Macle
Summary: A systematic review and pooled analysis of randomized control trials showed that catheter ablation of atrial fibrillation is associated with low rates of procedure-related complications and mortality, which have declined over the past decade.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Elena Arbelo, Nikolaos Dagres
Summary: This article critically reviews the recommendations of the 2020 ESC guidelines for the management of AF in light of two landmark trials, emphasizing the safety of contemporary rhythm control treatment and the importance of personalized treatment strategies.
Article
Physiology
Jae-Hyuk Lee, Oh-Seok Kwon, Hee Tae Yu, Tae-Hoon Kim, Jae-Sun Uhm, Boyoung Joung, Moon-Hyoung Lee, Hui-Nam Pak
Summary: Catheter ablation is an effective method for treating atrial fibrillation, but it may lead to atrial tissue damage and increase the risk of stiff LA physiology. Factors such as diabetes, E/Em ratio, LA pulse pressure, low LA voltage, empirical extra-PV ablation, and radiofrequency ablation duration are associated with stiff LA physiology after AFCA.
FRONTIERS IN PHYSIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Ramanathan Parameswaran, Ahmed M. Al-Kaisey, Jonathan M. Kalman
Summary: Catheter ablation is a key strategy for managing atrial fibrillation, with technological advancements focusing on improving safety and effectiveness. Guidelines recommend the procedure for symptomatic patients with paroxysmal or persistent AF, but evidence from trials is mixed. Pulmonary vein isolation remains a cornerstone technique in AF ablation, with ongoing developments in technology aimed at enhancing patient outcomes.
NATURE REVIEWS CARDIOLOGY
(2021)
Review
Immunology
Dishiwen Liu, Yajia Li, Qingyan Zhao
Summary: Atrial fibrillation (AF) is a serious healthcare burden with high morbidity and complications. Catheter ablation, although curable, currently has a low long-term success rate. Inflammation and fibrosis play significant roles in AF progression, and the artificial inflammatory response caused by catheter ablation may impact long-term prognosis. This review focuses on the different types of inflammatory cell death induced by various ablation techniques, as well as the structural and electrical remodeling caused by inflammation and its association with AF recurrence after catheter ablation. Pulsed-field ablation shows promise as a revolutionary innovation with faster, safer, better tissue selectivity, and less inflammatory response.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Lu Zhou, Liu He, Wei Wang, Changyi Li, Songnan Li, Ribo Tang, Caihua Sang, Nian Liu, Chenxi Jiang, Ronghui Yu, Deyong Long, Xin Du, Jianzeng Dong, Changsheng Ma
Summary: This study aimed to compare the effect of catheter ablation and drug therapy on recurrent AT/AF patients after AF catheter ablation. The results showed that repeat catheter ablation may significantly reduce the risk of composite cardiovascular mortality, ischemic stroke, and major bleeding events compared to medical therapy in patients with recurrent AT/AF after a catheter ablation procedure. However, there were no statistically significant differences between the two groups in terms of secondary endpoints.
Review
Cardiac & Cardiovascular Systems
Zhi-Jie Mao, Yan Pei, Hui Lin, Yin Xiang, Zhou-Qing Huang, Fang-Yi Xiao, Yi-He Chen
Summary: High-power radiofrequency catheter ablation shows superior efficacy in maintaining sinus rhythm for patients with atrial fibrillation, while also reducing procedure and fluoroscopy times. Additionally, there is no significant difference in the risk of complications between high-power and conventional-power ablation techniques.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Medicine, General & Internal
Francesco Maria Angelo Brasca, Roberto Mene, Giovanni Battista Perego
Summary: Atrial fibrillation (AF) is a common arrhythmia, especially in patients with structural heart disease (SHD). Catheter ablation (CA) has emerged as an effective strategy for rhythm control in AF patients and has potential benefits beyond symptom relief. This review summarizes the current knowledge of CA in SHD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Luigi Di Biase, Juan Carlos Diaz, Xiao-Dong Zhang, Jorge Romero
Summary: Pulsed field ablation is a novel energy source for the treatment of atrial fibrillation, with advantages in both safety and effectiveness compared to other energy sources, allowing targeted treatment and minimizing damage.
TRENDS IN CARDIOVASCULAR MEDICINE
(2022)